Orforglipron (Foundayo): Mechanism, Trial Results, Approvals
Orforglipron: where it is in development, what the trials show so far, and when it could reach patients.
- Active ingredient
- orforglipron
- Manufacturer
- Eli Lilly
- How it is taken
- Daily pill
- FDA-approved for
- Weight loss
A quick look at Foundayo
The half-life is 29 to 49 hours. After 39 h, half of the drug is gone, and about 3% remains after five half-lives (8.1 d).
In ATTAIN-1, over 72 weeks, people lost 11.1% of body weight on the drug, versus 2.1% with placebo.
In US dollars, the monthly figures cover the list price, along with self-pay offers. The maker's price page supplies each figure.
Sources: FDA label (DailyMed), Eli Lilly, pricinginfo.lilly.com.